对比分析雷贝拉唑分别与加味左金丸、富马酸伏诺拉生片两种药物作为维持阶段治疗方案的治疗成本和效果。

选取2020年1月至2023年9月新疆维吾尔自治区人民医院200例进入维持治疗阶段的胃食管反流病患者作为研究对象。将纳入患者随机均分为2组；A组采用雷贝拉唑和加味左金丸治疗，B组采用雷贝拉唑和富马酸伏诺拉生片治疗；通过对比2组患者治疗前后的症状（烧心、胸痛、反酸等），食管黏膜修复、生活质量改善程度，整体评价2组患者的治疗成本与效果。

A组总有效率为88%，B组总有效率为72%，2组治疗总有效率差异有统计学意义（P<0.05）。A组成本/效果比值（20.05%）与B组成本/效果比值（22.03%）比较，差异无统计学意义（P>0.05）；2组治疗成本/效果比值差异无统计学意义（P>0.05）。

对胃食管反流患者给予雷贝拉唑与加味左金丸联合治疗的成本和有效率较给予雷贝拉唑与富马酸伏诺拉生片高，2组的成本/效果比值相差不大。在不考虑成本的基础上，优先选择加味左金丸与雷贝拉唑联合治疗。

To compare the treatment costs and effectiveness of Rabeprazole combined with either Jiawei Zuojin Pill or Vonoprazan Fumarate Tablets as maintenance phase regimens.

A total of 200 patients with gastroesophageal reflux disease (GERD) entering the maintenance phase were enrolled from the People's Hospital of Xinjiang Uygur Autonomous Region between January 2020 and September 2023. The patients were randomly divided into two groups: Group A received Rabeprazole combined with Jiawei Zuojin Pill, while Group B received Rabeprazole combined with Vonoprazan Fumarate Tablets. The treatment costs and effectiveness of the two groups were comprehensively evaluated by comparing symptoms (heartburn, chest pain, acid regurgitation, etc.), esophageal mucosal healing, and improvements in quality of life before and after treatment.

The overall response rate was 88% in Group A and 72% in Group B, with a statistically significant difference (P<0.05). The cost-effectiveness ratio (CER) was 20.05% in Group A and 22.03% in Group B, showing no statistically significant difference (P>0.05). There was no statistically significant difference in the CER between the two groups (P<0.05).

While the combination therapy of Rabeprazole and Jiawei Zuojin Pill yielded a higher overall response rate and treatment cost compared to Rabeprazole combined with Vonoprazan Fumarate Tablets, the cost-effectiveness ratios between the two regimens were comparable. When cost is not a primary consideration, the combination of Jiawei Zuojin Pill and Rabeprazole is the preferred maintenance therapy option.